Sílvia Regina Ricci Lucas

Prof. Dr. Sílvia Regina Ricci Lucas


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ANAndrigo Barboza de Nardi
Andrigo Barboza de Nardi
CMCRISTINA MASSOCO
CRISTINA MASSOCO
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
FPFelipe Noleto de Paiva
Felipe Noleto de Paiva
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
MDMaria Dagli
Maria Dagli
Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease.

1 November 2015 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
VWValter M. Winkel
Valter M. Winkel
TPTatiana L. R. Pavan
Tatiana L. R. Pavan
VWVera A. B. F. Wirthl
Vera A. B. F. Wirthl
AAAna L. N. Alves
Ana L. N. Alves
SLSílvia Regina Ricci Lucas
Sílvia Regina Ricci Lucas
OBJECTIVE To characterize serum α-1 acid glycoprotein (AGP) and serum amyloid A (SAA) concentrations at diagnosis and during treatment in cats with lymphoma. ANIMALS 16 cats with various anatomic forms of lymphoma and 25 healthy cats. PROCEDURES Blood samples were collected from healthy cats once and from cats with lymphoma at diagnosis and 2-week intervals until the 12th week of antineoplastic treatment. Serum harvested from blood samples was assessed for AGP and SAA concentrations. Differences in serum AGP and SAA values were investigated between healthy cats and cats with lymphoma (at diagnosis) and, for cats with lymphoma, between diagnosis and various points during treatment. RESULTS Serum AGP and SAA concentrations were higher in cats with lymphoma at diagnosis (median, 832.60 and 1.03 μg/mL, respectively), compared with those in healthy cats (median, 269.85 and 0.10 μg/mL). Treatment resulted in a gradual decrease in serum AGP concentration after 4 weeks and in SAA concentration after 8 weeks of treatment, and these concentrations returned to values comparable with those of healthy cats by 12 weeks of treatment, by which point all cats had achieved complete remission of the disease. CONCLUSIONS AND CLINICAL RELEVANCE Serum AGP and SAA concentrations in cats with lymphoma were higher at diagnosis than after antineoplastic treatment. Decreases to values established for healthy cats corresponded with achievement of complete disease remission. Serum AGP and SAA may be useful protein markers for monitoring of antineoplastic treatment in cats with lymphoma.

26 March 2008 in Veterinary Clinical Pathology
Verified
Journal Article
Closed access
PDF file
AMAlexandre Merlo
Alexandre Merlo
BRBárbara Cristina Gagliano Rezende
Bárbara Cristina Gagliano Rezende
MFMaria Luisa Franchini
Maria Luisa Franchini
PMPaula Rumy Gonçalves Monteiro
Paula Rumy Gonçalves Monteiro
SLSílvia Regina Ricci Lucas
Sílvia Regina Ricci Lucas

1 April 2004 in Ciência Rural
Verified
Journal Article
Open access
PDF file
FEFernanda Elias
Fernanda Elias
SLSílvia Regina Ricci Lucas
Sílvia Regina Ricci Lucas
MHMitika Kuribayashi Hagiwara
Mitika Kuribayashi Hagiwara
MKMarcia Mery Kogika
Marcia Mery Kogika
RMRegina Mieko Sakata Mirandola
Regina Mieko Sakata Mirandola
A fragilidade osmótica eritrocitária (FOE) avalia a resistência osmótica das células vermelhas em concentrações decrescentes de solução salina. A resistência depende da forma, volume, tamanho, conteúdo de hemoglobina e meia vida dos eritrócitos, e pode ser alterada por vários fatores fisiológicos ou patológicos. Existem poucos relatos sobre a FOE em gatos. O objetivo deste estudo foi avaliar a FOE em gatos hígidos, com enfermidades hepáticas e naqueles com insuficiência renal. Foram estudados 27 animais divididos em três grupos. A hemólise 50% foi notada de forma similar em todos os grupos. Em 100% de hemólise, os eritrócitos de gatos com insuficiência renal e doença hepática mostraram maior fragilidade osmótica, embora esses animais apresentassem maiores níveis de colesterol sérico quando comparados aos gatos sadios do grupo controle. O achado de maior FOE mesmo com níveis elevados de colesterol pode estar associado a características metabólicas da espécie.

1 December 2010 in Brazilian Journal of Veterinary Research and Animal Science
Verified
Journal Article
Open access
PDF file
SLSílvia Regina Ricci Lucas
Sílvia Regina Ricci Lucas
AMAlexandre Merlo
Alexandre Merlo
RMRegina Mieko Sakata Mirandola
Regina Mieko Sakata Mirandola
TGThais Paione Gasparin
Thais Paione Gasparin
Ceruloplasmina (Cp) é uma proteína positiva de fase aguda, responsável pelo transporte de cobre e proteção das células e tecidos contra compostos oxidantes. O objetivo deste estudo foi avaliar as concentrações de Cp no momento do diagnóstico e durante a quimioterapia em cães com linfoma multicêntrico (LM). Cp foi mensurada utilizando-se a técnica da orto dianisina em dois grupos de cães: dez cães sadios (controle) e 13 cães com LM. Todos os cães foram submetidos à quimioterapia. Cães com sintomas de doenças intercorrentes ou que haviam sido previamente tratados com prednisona foram excluídos do estudo. Cp foi mensurada antes do início do tratamento e uma vez por semana durante o primeiro mês de quimioterapia e depois a intervalos de três semanas até a recidiva.para cães com LM, e até 16 semanas nos cães do grupo controle. ANOVA seguida pelo teste de Tukey foi usada para comparar os grupos. Não houve diferença entre a media das concentrações de Cp em cães com LM ao diagnóstico quando comparados aos cães sadios (p >; 0.05). Os níveis de Cp diminuíram significativamente na quarta semana de tratamento comparado ao momento do diagnóstico. Aumentos nas concentrações de Cp não foram observados na recidiva. Durante o tratamento, as concentrações de Cp em cães com linfoma não diferiram daquelas observadas nos animais do grupo controle submetidos à quimioterapia. Concluiu-se que os níveis de Cp nos cães com LM ao diagnóstico foram similares aos cães sadios, diminuiu quando se obteve a remissão e não se alterou na recidiva da doença.